Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumorsGeorge Mellgard, Che‐Kai Tsao, Matthew D. Galsky et al.|Journal of Cancer Research and Clinical Oncology|2022Cited by 23
Type, timing, and patient characteristics associated with immune-related adverse event development in patients with advanced solid tumors treated with immune checkpoint inhibitors.Qian Qin, Che‐Kai Tsao, George Mellgard et al.|Journal of Clinical Oncology|2020Cited by 16
Clinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysisQian Qin, Che‐Kai Tsao, George Mellgard et al.|Discover Oncology|2022Cited by 12
Risk Factors for Emergency Room and Hospital Care Among Patients With Solid Tumors on Immune Checkpoint Inhibitor TherapyAnish B. Parikh, Che‐Kai Tsao, Qian Qin et al.|American Journal of Clinical Oncology|2021Cited by 4
Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors.Vaibhav G. Patel, Che‐Kai Tsao, Qian Qin et al.|Journal of Clinical Oncology|2020Cited by 2